House Bill 533 Alabama 2026 Session

Summary

Primary Sponsor

Margie WilcoxRepresentative

Republican

Session

2026 Regular Session

Title

Public health, authorized forms of single-dose epinephrine used by public schools and authorized entities expanded

Summary

HB533 expands the forms of FDA-approved single-dose epinephrine that can be carried and used in schools and by authorized entities, and adds training, storage, and liability protections for anaphylaxis readiness.

What This Bill Does

It allows any FDA-approved single-dose premeasured epinephrine delivery system to be carried and self-administered by students and stocked/used by schools and authorized entities. It enables student self-administration for life-threatening allergic reactions and authorizes schools and other entities to provide epinephrine as needed under trained supervision. It requires schools to implement anaphylaxis preparedness programs with on-campus supplies, proper storage, staff training, emergency procedures, and incident reporting, while granting liability protections, and tying on-campus supply requirements to state funding; prescriptions under this act have a two-year validity and the measure takes effect October 1, 2026.

Who It Affects

• Students with severe allergies who may self-administer epinephrine at school or school events.
• School districts and nonpublic schools, including nurses and other staff who manage and supervise epinephrine administration.
• Authorized entities outside of schools (e.g., recreation camps, colleges/universities, day care facilities, youth leagues, workplaces) that may stock and provide epinephrine auto-injectors.
• Parents/guardians who must provide consent and medical information for self-administration.
• Physicians and pharmacists who prescribe or dispense epinephrine auto-injectors for use under this act.
• Department of Public Health and the State Board of Public Health, which oversee training, reporting, and program rules.

Key Provisions

• Expands approved medications to include any FDA-approved single-dose premeasured epinephrine delivery system for carrying and self-administration by students and for stocking/administration by schools and authorized entities.
• Allows self-administration by students for chronic conditions with required parent/guardian authorization, liability indemnification, physician authorization, dosage, frequency, and other details documented on file.
• Requires anaphylaxis preparedness programs in public schools with on-campus supplies, staff training by recognized entities, storage and handling standards, emergency procedures, and incident reporting to the Department of Public Health.
• Provides liability immunities for schools, trained personnel, training providers, and certain health professionals, with carve-outs for willful or wanton misconduct; clarifies roles regarding medical practice.
• Requires state funding to enforce on-campus epi supply requirements and establishes a two-year prescription validity for prescriptions issued under the act.
• Effective October 1, 2026.

AI-generated summary using openai/gpt-5-nano-2025-08-07 on Mar 3, 2026. May contain errors — refer to the official bill text for accuracy.

Subjects

Health